CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
- Registration Number
- NCT05436093
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Brief Summary
The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
-
- Aged >18 years old; ECOG 0 or 1;
-
- Patients with solid tumors;
-
- Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
-
- life expectancy >=12 weeks.
Exclusion Criteria
-
- Significant hepatic or renal dysfunction;
-
- Is pregnant or ready to pregnant;
-
- Cannot keep their states for half an hour;
-
- Refusal to join the clinical study;
-
- Suffering from claustrophobia or other mental diseases;
-
- Any other situation that researchers think it is not suitable to participate in the experiment.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 68Ga-ACN376 18F-FDG Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-ACN376 PET/CT scan.
- Primary Outcome Measures
Name Time Method Standardized uptake value（SUV） 2 years SUV is a semi-quantitative analysis index to describe the radioactive uptake of lesions, which has certain reference value for differentiating benign and malignant lesions。 The uptake of the tracer （68Ga-ACN376） in solid tumor lesions by measuring SUV on PET/CT.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Beijing cancer hospital
🇨🇳Beijing, Beijing, China